Inovio Pharmaceuticals IncFind Ratings Reports
INOVIO PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. INOVIO PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.52 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 38.08% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||10.38||8.11|
|Net Income ($mil)||-23.09||-8.04|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||89.66||146.79|
|Total Assets ($mil)||153.31||211.29|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||-202.44||-183.14|
|Return on Assets||-57.9||-12.61|
|Return on Equity||-83.87||-15.58|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||74.63||72.27|
|Div / share||0.0||0.0|
|Book value / share||1.42||2.37|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1847669.0||749592.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 4.24 indicates a premium versus the S&P 500 average of 3.07 and a significant discount versus the industry average of 11.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, INOVIO PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.
|INO NM||Peers 44.01||INO NM||Peers 43.69|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
INO's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
INO's P/CF is negative making the measure meaningless.
|INO NM||Peers 27.93||INO NA||Peers 0.55|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
INO's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|INO 4.24||Peers 11.44||INO -215.78||Peers -7.96|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
INO is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, INO is expected to significantly trail its peers on the basis of its earnings growth rate.
|INO 11.92||Peers 190.63||INO -13.52||Peers 434.91|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
INO is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
INO significantly trails its peers on the basis of sales growth